Barely Significant
← all excerpts

The impact of specific cytokine directed treatment on severe COVID-19.

Leukemia · 2021 · PMC8422045 · PMID 34493799

Europe PMCDOI
1
hedged sentence
0.0820
closest p · 1.6× alpha
0.0820
boldest claim

The sentences

showed a trendp = 0.082so close (0.05 < p ≤ 0.1)
The decrease in CIS was significant in ruxolitinib-treated patients ( p < 0.001) and showed a trend in the infliximab group ( p = 0.082), while there was no effect in the control group ( p = 0.992).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.